Source comparison
Melanotan-1 Before and After: Comparison by Dose and Timeline
The table below synthesizes clinical trial data and observational reports to show expected Melanotan-1 before and after outcomes across dose ranges and timelines. These benchmarks assume daily subcutaneous administration and baseline Fitzpatrick skin type II–I
This comparison does not assign a generated winner or score.
- The table below synthesizes clinical trial data and observational reports to show expected Melanotan-1 before and after outcomes across dose ranges and timelines. These benchmarks assume daily subcutaneous administration and baseline Fitzpatrick skin type II–III.
- 0.25mg daily (low dose)
- Minimal to none. Melanin synthesis initiated but not yet visible
- 1–2 shades darker than baseline, uniform distribution
- 2–3 shades darker, plateaus without UV exposure
- 3–5% nausea, rare flushing
- Conservative protocol for first-time users or maintenance after loading phase. Slow but predictable results
- 0.5mg daily (standard dose)
- Faint base tan visible in fair skin by day 21–28
- 2–3 shades darker, noticeable in before-and-after photos
- 3–4 shades darker with UV co-exposure, stable pigmentation
- 8–12% nausea, 2–4% headache
- Clinical trial standard dose. Balances efficacy and tolerability for most users, produces visible results by week 6
- 1mg daily (high dose)
- 1–2 shades visible by day 18–21, faster onset than 0.5mg
- 3–4 shades darker, approaching maximum achievable pigmentation
- 4–5 shades darker, no further increase without UV
- 15–20% nausea, 5–8% flushing, appetite suppression reported
- Faster results but higher side effect burden. Not proportionally more effective than 0.5mg for final pigmentation level
- 0.5mg + UV exposure (3×/week)
- 2 shades darker by week 4, synergistic effect visible early
- 4–5 shades darker, significantly more pigmentation than peptide alone
- 5–6 shades darker, maximum practical pigmentation for most skin types
- 8–12% nausea from peptide, UV-related erythema if overexposed
- Optimal protocol for users seeking maximal darkening. UV amplifies peptide effect without requiring dose escalation
- The data reveals a critical insight: doubling the dose from 0.5mg to 1mg daily does not double the pigmentation. It increases adverse events more than it increases melanin density. The dose-response curve flattens above 0.5mg, suggesting receptor saturation. Users chasing faster Melanotan-1 before and after transformations gain more from adding controlled UV exposure than from escalating dose beyond the clinical standard.